LumiraDx completes shares offering and private placement in $100M raise
Press releases | July 25, 2022
Fried Frank advised LumiraDx Limited (“LumiraDx”), a next-generation point of care diagnostics company, in connection with its public offering of common shares to raise gross proceeds of approximately US$75.25 million, which was underwritten by Goldman Sachs, Evercore, Silicon Valley Bank and Raymond James (the “Underwriters”).
Pursuant to the terms of the offering, LumiraDx also granted to the Underwriters the option, exercisable within 30 days of July 20, 2022, to purchase additional common shares. If such option is exercised in full, the gross proceeds from the offering will increase to approximately US$86.5 million.
Fried Frank also counseled LumiraDx in connection with its concurrent private placement of common shares to the Bill & Melinda Gates Foundation, to raise gross proceeds of approximately US$25 million. A current shareholder, the Bill & Melinda Gates Foundation has made a number of investments in LumiraDx in recent years. In connection with this transaction, the parties agreed to amend and restate the terms of an existing co-operation agreement to provide for the use of the proceeds of the private placement by LumiraDx.
The Fried Frank team was led by corporate partners Ian Lopez and John Satory, and included corporate partners Neil Caddy, Ashar Qureshi and Warren S. de Wied; tax partner Joseph E. Fox; and corporate associates Tiana Cherry, James Frecknall, Nick Skill, Adrian Packer, Eric Harper, Simon (Sangyun) Lee and Brett T. Masters.
This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.